Orion Group established Shanghai Anlai Biologics (hereinafter referred to as Anlai Biologics), a tuberculosis vaccine business corporation, in Shanghai, China in October 2024. Anlai Biologics is a bio company that aims to research, develop, produce, and sell vaccines and is currently focusing on developing a tuberculosis vaccine. It currently has an R&D center (Shanghai) and a bio factory (Shandongjing) in China and started operating the Shanghai R&D center in February 2025. It signed a joint development contract for a tuberculosis vaccine with Curatis, a global vaccine company, in March 2025 and is currently undergoing technology transfer for a tuberculosis vaccine.
In addition, in February 2025, the Beijing Thoracic Hospital under the Capital Medical University and the Beijing Tuberculosis Diagnosis and Treatment Technology Innovation Federation signed a Joint Agreement for Joint Development and Clinical Cooperation of Tuberculosis Vaccines to conduct joint clinical trials and commercialization in China.
To commercialize the tuberculosis vaccine, An Lai Biologics has formed and operated a multinational consultative group of clinical and non-clinical experts and regularly holds a 'Tuberculosis Vaccine Development Project Cooperation Forum' in which experts participate.
Tuberculosis is the deadliest epidemic in human history, and only BCG for infants and toddlers is commercialized worldwide, but there is no adult tuberculosis vaccine. In particular, the Chinese government is also interested in tuberculosis as a key management infectious disease, so the tuberculosis vaccine development project is expected to gain momentum.
Orion Group has approved phase 1 to 2b clinical trials of its tuberculosis vaccine through Anrai Biologics by 2026,
before entering phase 1 clinical trials, completing phase 2b clinical trials in mid-2030,
completing phase 3 clinical trials in 2034, and aiming for product licensing in 2035.